- Main event sparks institutional interest in U.S. crypto ETFs.
- Injective price rose 3.7% post-announcement.
- Market anticipates increased staking flows if ETF approved.
Canary Capital has registered a Delaware statutory trust to initiate a staked Injective ETF, as announced via Injective’s official Twitter. This action lays the groundwork for a U.S.-based investment product involving Injective (INJ).
Canary Capital has taken actionable steps by registering a Delaware trust to back a staking-enabled ETF featuring Injective (INJ), aiming at new investment avenues. This trust formation signals potential regulatory filings for a U.S. ETF.
Injective Labs, backing the Injective blockchain, collaborates closely in this initiative. These actions align with Canary’s history of ETF proposals targeting innovative staking mechanisms across a variety of notable altcoins.
The registration has led to positive sentiment among investors, observed through a 3.7% rise in Injective’s market price. Speculative flows suggest potential increased demand pending further developments and regulatory approvals.
This move could lead to significant financial impacts if the ETF gains approval. A positively impacted regulatory stance may enrich U.S. crypto investment landscapes, meeting institutional demands for compliant DeFi exposure.
The registration does not guarantee the ETF’s immediate listing but sets the stage for subsequent regulatory applications. The U.S. ETF market continues to explore crypto-based derivative products under emerging compliant frameworks.
Industry analysts reference precedents such as ETPs launched in Europe as parallels for potential outcomes. The Delaware trust positions Canary within a first-mover’s potential regulatory advantages, if approved, ahead of other U.S. crypto ETFs.
Injective Labs, Official Team, Injective, stated, “If the ETF is approved and operational, staking flows—and thus TVL on Injective—are expected to increase to facilitate yield generation by the ETF.”
